An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors.

Trial Profile

An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 04 Feb 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top